Advanced search
Show most relevant results first | Most recent results are first | Show use by person

Results 1-3 of 3 for drugs segment:7702252

Written Answers — Department of Health: Medicinal Products (14 Jul 2020)

Gerald Nash: 1096. To ask the Minister for Health the reason 12 children with SMA are still waiting to be treated with Spinraza one year after the drug was approved; the reason for the delay; when the matter will finally be addressed by the HSE; and if he will make a statement on the matter. [15076/20]

Written Answers — Department of Health: Medicinal Products (14 Jul 2020)

Gino Kenny: 1154. To ask the Minister for Health if his attention has been drawn to the number of children with spinal muscular atrophy eligible for treatment with the approved drug Spinraza; the number of those receiving the treatment; the reason for the delay in treatment for some of these children such as a child (details supplied); the way in which and when these issues will be addressed in order...

Written Answers — Department of Health: Medicinal Products (14 Jul 2020)

Stephen Donnelly: ...for medicine pricing and reimbursement decisions, in accordance with the Health (Pricing and Supply of Medical Goods) Act 2013. On 11 June 2019, the HSE Leadership Team approved access to the drug Nusinersen (Spinraza) for children with Spinal Muscular Atrophy (SMA) Type I, II or III on an exceptional and individualised basis. The HSE decision process in relation to Spinraza...

   Advanced search
Show most relevant results first | Most recent results are first | Show use by person